RedHill Biopharma (RDHL) Work In Process (2021 - 2024)

RedHill Biopharma (RDHL) has 4 years of Work In Process data on file, last reported at $308000.0 in Q4 2024.

• Work In Process for Q4 2024 came in at $308000.0, up 32.19% year-over-year; the trailing twelve-month figure through Dec 2024 was $308000.0 (up 32.19% YoY), and the FY2024 annual result was $308000.0, up 32.19% from the prior year.
• Work In Process advanced to $308000.0 in Q4 2024 per RDHL's latest filing, from $233000.0 in the prior quarter.
• Over five years, Work In Process peaked at $5.2 million in Q4 2021 and troughed at $233000.0 in Q4 2023.
• A 4-year average of $2.0 million and a median of $1.3 million in 2022 frame the typical range for Work In Process.
• The sharpest annual moves came in 2023 and 2024: Work In Process plunged 90.23% in 2023, then soared 32.19% in 2024.
• A 4-year view of Work In Process shows it stood at $5.2 million in 2021, then plunged by 54.09% to $2.4 million in 2022, then sank by 90.23% to $233000.0 in 2023, then soared by 32.19% to $308000.0 in 2024.
• Business Quant data shows RDHL's Work In Process at $308000.0 in Q4 2024, $233000.0 in Q4 2023, and $2.4 million in Q4 2022.